The Latest Breaking News from BristolMyers Squibb

With BioNTech sealing a blockbuster $11 billion cancer deal with Bristol-Myers Squibb, should investors be loading up on this rising biotech star?

The fear of a trade war over pharmaceuticals between the EU and the US has been avoided for now, but the European Commission remains on guard, considering further tariff deployments likely.

As the biopharma industry booms with breakthrough treatments and growing demand, this high-yield healthcare stock just received a strong vote of confidence from insider buying.

Bristol-Myers Squibb is poised to announce its second-quarter results this month, and analysts forecast a single-digit decline in the company’s bottom-line figure.

Looking for yield? Here's 3 healthcare stocks with the highest yields today.

Bristol-Myers Squibb stock has significantly trailed the broader market this year, and Wall Street remains wary on the stock’s prospects.

Bristol Myers has reported better-than-expected 4th-quarter results, indicating positive performance for the company.

The move is expected to cut costs in a few years for some patients but faces litigation from the drugmakers and heavy criticism from Republican lawmakers.

September S&P 500 futures (ESU23) are up +0.59%, and September Nasdaq 100 E-Mini futures (NQU23) are up +1.20% this morning after three major U.S. benchmark indices ended the regular session mixed as market participants digested Federal Reserve Chair Jerome Powell’s comments following the Fed’s widely expected 25 basis point rate…